ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

Arrowhead Pharmaceuticals (ARWR) is drawing fresh Wall Street attention after Goldman Sachs resumed coverage of the biotechnology company with a ‘Neutral’ rating and $74 price target. The firm highlighted its preference for biotech companies with “de-risked commercial execution and underappreciated…